Animal experiments show that LA85 can protect immune organs, regulate protein expression in related pathways, and play an immune regulatory role. At the same time, LA85 can effectively inhibit pathogenic bacteria such as Escherichia coli, Salmonella and Staphylococcus aureus.

It effectively promotes the proliferation of macrophages RAW264.7, increases the phagocytosis index of RAW264.7 cells, promotes the production of TNF-α, IL-10 and other cytokines, and plays an immune regulatory role. At the same time, this strain has a broad antibacterial spectrum and can effectively inhibit pathogenic bacteria such as Staphylococcus aureus, Escherichia coli, Salmonella, Streptococcus mitis, and Klebsiella pneumoniae.

It effectively inhibits the growth of Listeria monocytogenes, has a protective effect on intestinal epithelial cell strain (HT-29) infection and mouse liver and spleen infection caused by Listeria monocytogenes, can protect immune organs, and has immunomodulatory potential.

It has the ability to produce high short-chain fatty acids. Animal experiments show that LC89 can effectively reduce the content of inflammatory factors in rats with colitis, regulate immunity, and alleviate inflammatory bowel disease. Population trials have found that LC89 can significantly improve the degree of abdominal pain, frequency of diarrhea and dietary appetite in people with inflammatory bowel disease.

High-yield extracellular polysaccharides can improve the proliferation and phagocytosis ability of macrophages RAW264.7, play an immune regulatory role, and can also efficiently scavenge free radicals and inhibit pathogens.